Xinhua News Agency, Beijing (Reporter Zhang Zhaohui) — On July 16, the official website of the National Medical Products Administration showed that Qilu Pharmaceutical's Entrectinib Tablets (Tweino), for the treatment of HIV-1 (Human Immunodeficiency Virus Type 1) infection, were approved for marketing.
AIDS is a contagious disease caused by the infection of the human immunodeficiency virus (HIV). AIDS cannot be completely cured at present, and patients need to take multiple medications for a long term. Entecavir and Lamivudine Tablets are suitable for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥35kg.
Entecavir and Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate Tablets consist of Entecavir, Rilpivirine Hydrochloride, and Tenofovir Alafenamide Fumarate. Entecavir is a nucleoside reverse transcriptase inhibitor that blocks the synthesis of viral DNA chains. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor that inhibits viral replication by non-competitively inhibiting HIV-1 reverse transcriptase and exhibits broad-spectrum antiviral activity against various HIV-1 subtypes. Tenofovir Alafenamide is converted into its active form, Tenofovir, in the body, and then through phosphorylation, it is transformed into Tenofovir Diphosphate, which induces the termination of viral DNA chain replication.
The combination regimen of three drugs has proven efficacy and is a guideline-recommended antiviral treatment for adult and adolescent patients who are treatment-naive. The single-tablet formulation is more convenient to take, requiring only one tablet per day, which helps reduce the medication burden on patients and improve adherence.
Proofread by Baoqing Liu